South Texas Accelerated Research Therapeutics (START)

Grand Rapids, MI
(888) 803-1766

Sorting 1 by

Accepting patients

MGD024

A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies
Learn more
  • Bispecific Antibody
  • Phase 1
Get personalized results in 60 seconds
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials